Evidence map›Paper›PMID 40960691›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Habitat-aware radiomics and adaptive 2.5D deep learning predict treatment response and long-term survival in ESCC patients undergoing neoadjuvant chemoimmunotherapy.

Xing Gao, Liping Yang, Tianyu She, Fei Wang, Hongchao Ding, Yanhong Lu, Yuchao Xu, Yuan Wang, Ping Li, Xiaoyi Duan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. The predictive value ofFrontiers in medicine · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xing Gao *Department of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Liping Yang *Department of PET-CT, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China.
Tianyu SheDepartment of Ultrasound, Xi'an Electric Power Central Hospital, Xi'an, China.
Fei WangDepartment of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hongchao DingDepartment of Magnetic Resonance Imaging, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yanhong LuDepartment of Pathology, Heilongjiang Provincial Hospital, Harbin, China.
Yuchao XuSchool of Nuclear Science and Technology, University of South China, Hengyang, Hunan, China.
Yuan WangDepartment of Ultrasound, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Ping LiDepartment of PET-CT, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. lipinghmu@163.com.
Xiaoyi DuanDepartment of PET-CT, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China. duanxy@mail.xjtu.edu.cn.
Xiaoping LengDepartment of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. xpleng@ems.hrbmu.edu.cn.

Funding

Longjiang science and Technology Talent Wild ChunYan Support Project CYCX24003Natural Science Foundation of China U22A20346
6 · The paper itself

Abstract

purposeCurrent radiomic approaches inadequately resolve spatial intratumoral heterogeneity (ITH) in esophageal squamous cell carcinoma (ESCC), limiting neoadjuvant chemoimmunotherapy (NACI) response prediction. We propose an interpretable multimodal framework to: (1) quantitatively map intra-/peritumoral heterogeneity via voxel-wise habitat radiomics; (2) model cross-sectional tumor biology using 2.5D deep learning; and (3) establish mechanism-driven biomarkers via SHAP interpretability to identify resistance-linked subregions.

methodsThis dual-center retrospective study analyzed 269 treatment-naïve ESCC patients with baseline PET/CT (training: n = 144; validation: n = 62; test: n = 63). Habitat radiomics delineated tumor subregions via K-means clustering (Calinski-Harabasz-optimized) on PET/CT, extracting 1,834 radiomic features per modality. A multi-stage pipeline (univariate filtering, mRMR, LASSO regression) selected 32 discriminative features. The 2.5D model aggregated ± 4 peri-tumoral slices, fusing PET/CT via MixUp channels using a fine-tuned ResNet50 (ImageNet-pretrained), with multi-instance learning (MIL) translating slice-level features to patient-level predictions. Habitat features, MIL signatures, and clinical variables were integrated via five-classifier ensemble (ExtraTrees/SVM/RandomForest) and Crossformer architecture (SMOTE-balanced). Validation included AUC, sensitivity, specificity, calibration curves, decision curve analysis (DCA), survival metrics (C-index, Kaplan-Meier), and interpretability (SHAP, Grad-CAM).

resultsHabitat radiomics achieved superior validation AUC (0.865, 95% CI: 0.778-0.953), outperforming conventional radiomics (ΔAUC + 3.6%, P < 0.01) and clinical models (ΔAUC + 6.4%, P < 0.001). SHAP identified the invasive front (H2) as dominant predictor (40% of top features), with wavelet_LHH_firstorder_Entropy showing highest impact (SHAP = + 0.42). The 2.5D MIL model demonstrated strong generalizability (validation AUC: 0.861). The combined model achieved state-of-the-art test performance (AUC = 0.824, sensitivity = 0.875) with superior calibration (Hosmer-Lemeshow P > 0.800), effective survival stratification (test C-index: 0.809), and 23-41% net benefit improvement in DCA.

conclusionIntegrating habitat radiomics and 2.5D deep learning enables interpretable dual diagnostic-prognostic stratification in ESCC, advancing precision oncology by decoding spatial heterogeneity.

Indexed as

Deep LearningEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaImage Processing, Computer-AssistedImmunotherapyNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadiomicsRetrospective StudiesTreatment Outcome2.5D deep learningClinical decision supportHabitat analysisMulti-instance learningRadiomicsTumor spatial heterogeneity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.